Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01411267
Other study ID # T2009-004
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 1, 2011
Est. completion date September 12, 2013

Study information

Verified date March 2022
Source Therapeutic Advances in Childhood Leukemia Consortium
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).


Description:

This is a study for pediatric patients with relapsed acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). Some people diagnosed with leukemia have changes in a receptor located on the surface of white blood cells called FLT3. This is known as a FLT3 mutation. FLT3 plays an important role in the way cells grow and divide. In normal cells, the FLT3 receptor is switched off most of the time and only switches on when it gets a chemical signal from outside. But cells with the FLT3 mutation have the grow signal permanently switched on. This means leukemia cells with the FLT3 mutation are growing and dividing all the time. Doctors have found that people with leukemia cells that carry FLT3 mutations are less likely to go into remission with chemotherapy and have a higher risk of the leukemia coming back after treatment. This is a study of an investigational drug called AC220. AC220 is considered investigational because it has not been approved in the United States by the Food and Drug Administration (FDA). AC220 is a drug which is able to "turn off" the FLT3 grow signal. AC220 will be given with cytarabine and etoposide to treat the relapsed leukemia. This is a phase I study, which means that the study is being done to find the highest dose of AC220 that can be given safely with the drugs cytarabine and etoposide to children and young adults.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date September 12, 2013
Est. primary completion date September 12, 2013
Accepts healthy volunteers No
Gender All
Age group 1 Month to 21 Years
Eligibility Inclusion Criteria: - Patients must be greater than 1 month and = 21 years of age at study entry. - Patients must have a diagnosis of relapsed/refractory AML, ALL or acute leukemia of ambiguous lineage and meet the following criteria: 1. Patients with AML or leukemia with ambiguous lineage must have greater than or equal to 5% blasts in the bone marrow. 2. Patients with ALL must have an M3 marrow (marrow blasts >25%). 3. Patients with ALL must have MLL gene rearrangement or hyperdiploid >50 chromosomes. 4. Patients with treatment related AML (t-AML) are eligible, provided they meet all other eligibility criteria. - Karnofsky > 50% for patients >16 years of age and Lansky >50% for patients =16 years of age. - Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. - Myelosuppressive chemotherapy: - Patients with ALL who relapse during standard maintenance therapy are eligible at time of relapse. - For patients with ALL and AML who relapse while they are receiving cytotoxic therapy, at least 14 days must have elapsed since the completion of cytotoxic therapy. - Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of AC220. - Patients who have received other FLT3 inhibitors (ex. lestaurtinib, sorafenib) are eligible for this study. - Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor. - Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair. - XRT: 2 wks must have elapsed since local palliative XRT for CNS chloromas; No washout period is necessary for other chloromas; at least 3 months must have elapsed if prior TBI, craniospinal XRT. - Hematopoetic Stem Cell Transplant: At least 90 days must have elapsed since hematopoietic stem cell transplant (HSCT) and patients must not have active GVHD. - Patient must have adequate renal and hepatic functions as indicated by the following laboratory values: - Patients must have a calculated creatinine clearance or radioisotope GFR =70mL/min/1.73m2 or a normal serum creatinine based on age/gender. - Total bilirubin <1.5 x ULN for age or normal conjugated bilirubin. - Alanine transaminase (ALT) <5 × ULN (unless related to leukemic involvement). - Patient must have a shortening fraction of = 27% by echocardiogram, OR an ejection fraction of = 50% by radionuclide angiogram. - Reproductive Function - Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment. - Female patients with infants must agree not to breastfeed their infants while on this study. - Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment. Exclusion Criteria: - Patients will be excluded if they have CNS 3 disease. - Patients will be excluded if they have uncontrolled or significant cardiovascular disease, including: - A myocardial infarction within 12 months. - Uncontrolled angina within 6 months. - Diagnosed or suspected congenital long QT syndrome or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes [TdP]); any history of arrhythmia will be discussed with the Sponsor's Medical Monitor prior to patient's entry into the study. - Prolonged QTcF interval on pre-entry ECG (=450 ms). - Any history of second or third degree heart block (may be eligible if the patient currently has a pacemaker). - Heart rate < 50/minute on pre-entry ECG. - Uncontrolled hypertension. - Complete left bundle branch block. - Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or TdP. - Patients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient needs to be off pressors and have negative blood cultures for 48 hours. - Patient is receiving or plans to receive concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol. - Any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results. - Patients who are concurrently receiving CYP3A4 and 5 inhibitors and inducers

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age: 20 mg for patients age <1 yr 30 mg for patients age 1-1.99 years of age 50 mg for patients age 2-2.99 years of age 70 mg for patients >3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age 6 mg for patients age < 1yr 8 mg for patients age 1-1.99 10 mg for patients age 2-2.99 12 mg for patients 3-8.99 years of age 15 mg for patients >9 years of age

Locations

Country Name City State
United States Children's Healthcare of Atlanta, Emory University Atlanta Georgia
United States The Children's Hospital, University of Colorado Aurora Colorado
United States Johns Hopkins University Baltimore Maryland
United States Dana Farber Boston Massachusetts
United States Levine Children's Hospital at Carolinas Medical Center Charlotte North Carolina
United States Children's Mercy Hospitals and Clinics Kansas City Missouri
United States Childrens Hospital Los Angeles Los Angeles California
United States Children's Hospital Central California Madera California
United States Oregon Health and Science University Portland Oregon
United States UCSF School of Medicine San Francisco California
United States Seattle Children's Hospital Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Therapeutic Advances in Childhood Leukemia Consortium Ambit Biosciences Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Ch — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy. Plasma inhibitor activity (PIA) will be measured Pre-treatment and on Days 7, 14, 21 and 28 of Course 1. For the MTD to be considered biologically active, we will require that 7 of 9 patients achieve PIA of > 90% at 3 of 4 trough time points. 4 weeks from therapy start
Secondary Disease Response Possible outcomes are: Complete Remission (CR), Complete Remission without Platelet Recovery (CRp), complete response with incomplete hematologic recovery (CRi), Stable Disease, Progressive Disease, Induction Death, or Relapse 10 weeks
Secondary Count of Participants According to Inhibition of FLT3 Phosphorylation PIA samples will be collected pre-treatment and on Days 7, 14, 21 and 28 of Course 1. 4 weeks from therapy start
See also
  Status Clinical Trial Phase
Recruiting NCT05043571 - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia Phase 1
Recruiting NCT05495035 - Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Phase 1
Completed NCT00991133 - A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) Phase 1
Active, not recruiting NCT05440409 - CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed NCT01861002 - A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML Phase 1
Terminated NCT01100658 - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors N/A
Completed NCT01321346 - A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Phase 1
Completed NCT01896752 - Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL N/A
Completed NCT01614197 - A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Phase 1
Recruiting NCT05429905 - Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase 1/Phase 2
Recruiting NCT02879643 - Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL Phase 1
Recruiting NCT03022747 - Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol Phase 2
Active, not recruiting NCT03817320 - PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Phase 1/Phase 2
Terminated NCT05611086 - N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia Phase 4
Terminated NCT01186328 - EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Phase 1
Completed NCT02906371 - Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome Phase 1
Recruiting NCT05038696 - ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. Phase 1